Immunotherapy for leprosy and tuberculosis

作者: J. L. Stanford

DOI: 10.1007/978-3-0348-9146-2_13

关键词:

摘要: Prior to the development of effective chemotherapy for tuberculosis and leprosy, only approach active treatment these diseases was enhance patients’ own immunity. Attempts accomplish this were an obvious goal once infectious nature became appreciated from work Villemin in 1870’s. The observations that many persons close contact with either leprosy or did not develop disease, disease followed a very chronic course considerable proportion patients, others overcame their showed potential such approach. It is often forgotten prior 1940’s discovery streptomycin as 50% patients clinically manifest actually recovered. proclivity toward natural recovery has made assessment early methods so difficult, there claims treatments probably depended on case selection “efficacy”. earliest attempts at planned immunotherapy may have been Paris, but first person claim real success, experimental support claims, Robert Koch [1].

参考文章(64)
Aranzazu N, Pinardi Me, Convit J, Alvarado J, Reyes O, Ulrich M, Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda-negative contacts. International Journal of Leprosy and Other Mycobacterial Diseases. ,vol. 50, pp. 415- 424 ,(1982)
Chaudhuri S, Talwar Gp, Fotedar A, Lepromin conversion in repeatedly lepromin negative BL/LL patients after immunization with autoclaved Mycobacterium w. International Journal of Leprosy and Other Mycobacterial Diseases. ,vol. 51, pp. 159- ,(1983)
R C Potts, J H Gibbs, J S Beck, J Stanford, J M Grange, M I Ilias, S M Morley, T Kardjito, R A Brown, The cellular responses of tuberculosis and leprosy patients and of healthy controls in skin tests to 'new tuberculin' and leprosin A. Clinical and Experimental Immunology. ,vol. 64, pp. 484- ,(1986)
P. M. NYE, J. L. STANFORD, G. A. W. ROOK, P. LAWTON, M. MACGREGOR, C. REILY, D. HUMBER, P. OREGE, C. R. REVANKAR, J. TERENCIO DE LAS AGUAS, P. TORRES, Suppressor determinants of mycobacteria and their potential relevance to leprosy. Leprosy Review. ,vol. 57, pp. 147- ,(1986) , 10.5935/0305-7518.19860018
Ronald T. Mitsuyasu, Steven A. Miles, Samuel R Saks, David Aboulafia, Intravenous recombinant tumor necrosis factor in the treatment of AIDS-related Kaposi's sarcoma. Journal of Acquired Immune Deficiency Syndromes. ,vol. 2, pp. 54- 58 ,(1989)
W. Van. Eden, G. A. W. Rook, J. L. Stanford, R. R. P. De. Vries, HLA-DR3 associated genetic control of response to multiple skin tests with new tuberculins. Clinical and Experimental Immunology. ,vol. 52, pp. 287- 292 ,(1983)
E. Filley, G. A. W. Rook, D. Nelson, K. Tung, J. Steele, M. Waters, D. Wagner, A. Andreoli, T. Rademacher, R. Dwek, A transient rise in agalactosyl IgG correlating with free interleukin 2 receptors, during episodes of erythema nodosum leprosum. Clinical and Experimental Immunology. ,vol. 76, pp. 343- 347 ,(1989)
Baily Gv, Tuberculosis prevention Trial, Madras. Indian Journal of Medical Research. pp. 1- 74 ,(1980)
J. L. Stanford, J. K. C. Wong, A Study of the Relationship between Nocardia and Mycobacterium diernhoferi—A Typical Fast Growing Mycobacterium British journal of experimental pathology. ,vol. 55, pp. 291- 295 ,(1974)
G. A. Rook, G. Kronvall, J. Convit, R. J. Rees, T. Godal, G. P. Walsh, J. L. Stanford, Preliminary taxonomic studies on the leprosy bacillus. British journal of experimental pathology. ,vol. 56, pp. 579- 585 ,(1975)